Antihypertensive agent 7 

Antihypertensive agent 7 is a vasodilator. Antihypertensive agent 7 acts on vascular endothelial cells to activate the PI3K/AKT signaling axis, increase phosphorylated eNOS, release NO, activate the sGC/cGMP pathway in smooth muscle cells, and synergistically activate multiple K⁺ channels in vascular smooth muscle (K_ir/K_v/K_Ca/K_ATP, thereby inducing endothelium-dependent vasodilation. Antihypertensive agent 7 can be used in the research of hypertension^[1].

Antihypertensive agent 7 (Compound A24) at concentrations of 3.75-60 μM induces potent, concentration-dependent relaxation in endothelium-intact rat thoracic aortic rings, with an EC₅₀ of 21.47 μM and a maximum relaxation rate of 97.24%^[1].
The vasodilatory effect of Antihypertensive agent 7 (3.75-60 μM) is mainly endothelium-dependent, as the maximum relaxation amplitude of endothelium-denuded rat thoracic aortic rings is significantly reduced to 38.49%^[1].
The vasodilatory effect of Antihypertensive agent 7 (3.75-60 μM; 20 min) on intact endothelium rat thoracic aortic rings is mediated by the PI3K/AKT signaling pathway, as pretreatment with pathway inhibitors significantly attenuates this response^[1].
The vasodilatory effect of Antihypertensive agent 7 (3.75-60 μM; 20 min) on rat thoracic aortic rings with intact endothelium involves the eNOS/NO/sGC signaling pathway, as pretreatment with pathway inhibitors significantly attenuates this response^[1].
Antihypertensive agent 7 (60 μM; 15-60 min) activates AKT in a time-dependent manner in human umbilical vein endothelial cells, with the maximum phosphorylation level observed after treatment with 60 μM for 30 min^[1].
Antihypertensive agent 7 (15-60 μM; 30 min) increases the phosphorylation levels of AKT and eNOS in human umbilical vein endothelial cells in a concentration-dependent manner^[1].
The vasodilatory effect of Antihypertensive agent 7 (3.75-60 μM; 20 min) on endothelium-intact rat thoracic aortic rings is independent of the activation of muscarinic receptors and β-adrenergic receptors^[1].
Antihypertensive agent 7 (3.75-60 μM; 20 min) exerts vasodilatory effects on rat thoracic aortic rings with intact endothelium independent of the PGI₂ signaling pathway^[1].
The vasodilatory effect of Antihypertensive agent 7 (3.75-60 μM; 20 min) on endothelium-intact rat thoracic aortic rings involves the activation of multiple potassium channel subtypes, including K_ATP, K_Ca, K_V and K_IR channels^[1].
Antihypertensive agent 7 (60 μM) does not affect ROCCs- or VDCCs-mediated vasoconstriction in rat thoracic aortic rings^[1].
Antihypertensive agent 7 (60 μM) does not affect vasoconstriction mediated by sarcoplasmic reticulum Ca²⁺ release in rat thoracic aortic rings^[1].
Antihypertensive agent 7 (2.5-80 μM; 24 h) exhibits no significant cytotoxicity against human umbilical vein endothelial cells at concentrations up to 80 μM following 24 h of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antihypertensive agent 7 (Compound A24) (20-60 mg/kg; i.p.; daily; 5 weeks) dose-dependently lowers systolic and diastolic blood pressure in L-NAME (HY-18729)-induced hypertensive rats, while also improving body weight gain and reducing multi-organ pathological damage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

371.41

C₂₀H₂₂FN₃O₃

CC(N1CCC(CC1)NC(C2=CC(C3=C(OC)C=C(F)C=C3)=CC=N2)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang YL, et al.. Discovery of pyridine amide derivatives exhibiting vasodilatory activity. Bioorganic chemistry. 2026 Sep 05;179:110050.